PDCD1 and cancer: To date, four anti-PDCD1 mAbs have been approved by FDA and/or EMA for different cancer types, nivolumab (OPDIVO®, mAbID 424), pembrolizumab (KEYTRUDA®, mAbID 472), dostarlimab (JEMPERLI, mAbID 849) and cemiplimab (LIBTAYO®, mAbID 846).